DE69429768T2 - Diagnose und behandlung von erektilen funktionsstörungen - Google Patents

Diagnose und behandlung von erektilen funktionsstörungen

Info

Publication number
DE69429768T2
DE69429768T2 DE69429768T DE69429768T DE69429768T2 DE 69429768 T2 DE69429768 T2 DE 69429768T2 DE 69429768 T DE69429768 T DE 69429768T DE 69429768 T DE69429768 T DE 69429768T DE 69429768 T2 DE69429768 T2 DE 69429768T2
Authority
DE
Germany
Prior art keywords
diagnosis
treatment
erectile dysfunctions
dysfunctions
erectile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429768T
Other languages
English (en)
Other versions
DE69429768D1 (de
Inventor
Mac E Hadley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Competitive Technologies Inc
Original Assignee
Competitive Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US4315993A priority Critical
Application filed by Competitive Technologies Inc filed Critical Competitive Technologies Inc
Priority to PCT/US1994/003677 priority patent/WO1994022460A1/en
Application granted granted Critical
Publication of DE69429768T2 publication Critical patent/DE69429768T2/de
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68Melanocyte-stimulating hormone [MSH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695Corticotropin [ACTH]
    • C07K14/6955Corticotropin [ACTH] with at least 1 amino acid in D-form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/811Test for named disease, body condition or organ function
DE69429768T 1993-04-05 1994-04-04 Diagnose und behandlung von erektilen funktionsstörungen Expired - Lifetime DE69429768T2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US4315993A true 1993-04-05 1993-04-05
PCT/US1994/003677 WO1994022460A1 (en) 1993-04-05 1994-04-04 Diagnosis and treatment of erectile dysfunction

Publications (1)

Publication Number Publication Date
DE69429768T2 true DE69429768T2 (de) 2002-09-19

Family

ID=21925795

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69429768T Expired - Lifetime DE69429768T2 (de) 1993-04-05 1994-04-04 Diagnose und behandlung von erektilen funktionsstörungen
DE69429768A Expired - Lifetime DE69429768D1 (de) 1993-04-05 1994-04-04 Diagnose und behandlung von erektilen funktionsstörungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69429768A Expired - Lifetime DE69429768D1 (de) 1993-04-05 1994-04-04 Diagnose und behandlung von erektilen funktionsstörungen

Country Status (5)

Country Link
US (2) US5576290A (de)
EP (1) EP0696919B1 (de)
JP (1) JP3204510B2 (de)
DE (2) DE69429768T2 (de)
WO (1) WO1994022460A1 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69429768T2 (de) * 1993-04-05 2002-09-19 Competitive Tech Inc Diagnose und behandlung von erektilen funktionsstörungen
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US5958877A (en) * 1995-05-18 1999-09-28 Wimalawansa; Sunil J. Method for counteracting vasospasms, ischemia, renal failure, and treating male impotence using calcitonin gene related peptide
AU5348098A (en) * 1996-12-17 1998-07-15 Quadrant Holdings Cambridge Limited Melanocortins
CA2284773A1 (en) * 1997-03-24 1998-10-01 Roger Dixon Systems and methods for monitoring and evaluating penile tumescence
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
CA2295595A1 (en) 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
AU9603198A (en) * 1997-10-09 1999-05-03 Rutgers University Process to identify a sexual response-stimulating substance
US6593369B2 (en) 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US20020004529A1 (en) * 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
AU751182B2 (en) * 1997-12-02 2002-08-08 Archimedes Development Limited Compositions for nasal administration
US6284735B1 (en) * 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
WO1999055679A1 (en) * 1998-04-28 1999-11-04 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
US6046240A (en) * 1998-05-01 2000-04-04 Harvard Scientific Corporation Methods for treating female sexual dysfunction
US6001845A (en) * 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US7087240B1 (en) 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
PL348817A1 (en) * 1998-12-14 2002-06-17 Cellegy Pharmaceuticals Compositions and methods for the treatment of anorectal disorders
CA2362918A1 (en) * 1999-03-08 2000-09-14 Joanne Waldstreicher Methods and compositions for treating erectile dysfunction
CA2365782A1 (en) 1999-04-30 2000-11-09 William E. Pullman Treatment of female arousal disorder
JP2003505435A (ja) 1999-06-04 2003-02-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−4受容体ゴニストとしての置換ピペリジン
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
KR101021632B1 (ko) 1999-06-29 2011-03-17 팔라틴 테크놀러지즈 인코포레이티드 성기능 장애 치료용 조성물 및 치료 방법
US6211156B1 (en) * 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
US6650943B1 (en) 2000-04-07 2003-11-18 Advanced Bionics Corporation Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction
EP1320366A4 (de) 2000-08-23 2005-04-06 Merck & Co Inc Substituierte piperidine als melanocortin-rezeptoragonisten
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US7128930B1 (en) 2000-09-01 2006-10-31 Meir S. Sacks Compositions and methods for treating sexual dysfunction
AU2002245104B2 (en) * 2000-12-11 2006-08-17 Testocreme, Llc Topical testosterone formulations and associated methods
AU2002238106A1 (en) * 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
BR0207658A (pt) 2001-02-28 2005-10-25 Merck & Co Inc Métodos para o tratamento ou a prevenção de distúrbios, doenças ou condições responsivas à ativação do receptor de melanocortina-4, de obesidade, de diabetes melito, de disfunção sexual masculina ou feminina, e de disfunção erétil em um mamìfero que disto necessita, e, composição farmacêutica
AU2002255597B8 (en) * 2001-02-28 2006-10-26 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor agonists
US7012084B2 (en) 2001-02-28 2006-03-14 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
US6885895B1 (en) 2001-04-26 2005-04-26 Advanced Bionics Corporation Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
JP2004534851A (ja) * 2001-07-11 2004-11-18 パラチン テクノロジーズ インク. メラノコルチン受容体に特異的な線状および環状ペプチド
AT411021T (de) * 2001-07-18 2008-10-15 Merck & Co Inc Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
KR20090130196A (ko) 2001-10-20 2009-12-18 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 플리반세린을 포함하는 성욕 장애 치료용 약제학적 조성물
US6873883B2 (en) * 2001-12-26 2005-03-29 Hewlett-Packard Development Company, L.P. Adaptive fan controller for a computer system
US6809079B2 (en) * 2002-01-08 2004-10-26 Vasogenix Pharmaceuticals, Inc. Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
BR0305628A (pt) * 2002-07-09 2004-09-08 Palatin Technologies Inc Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
AU2003268493A1 (en) * 2002-09-11 2004-04-30 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
US6892568B2 (en) * 2003-02-03 2005-05-17 Honda Giken Kogyo Kabushiki Kaisha Noise detection system and method
WO2004078716A1 (en) * 2003-03-03 2004-09-16 Merck & Co. Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
US20050101535A1 (en) * 2003-05-06 2005-05-12 Rosenstein David H. Use of a synthetic alpha-melanocyte stimulating hormone agonist to decrease steroid induced weight gain
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20080200376A1 (en) * 2004-10-29 2008-08-21 Maccoss Malcolm Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction
WO2006060873A1 (en) * 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
US20080269233A1 (en) * 2005-08-04 2008-10-30 Mark David Andrews Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
EP1940842B1 (de) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylierte spiropiperidinderivate als modulatoren des melanocortin-4-rezeptors
ES2693745T3 (es) 2005-10-12 2018-12-13 Unimed Pharmaceuticals, Llc Gel de testosterona mejorado para su uso en el tratamiento del hipogonadismo
EP1940401B1 (de) * 2005-10-18 2012-07-11 Merck Sharp & Dohme Corp. Acylierte spiropiperidin-derivate als melanocortin-4-rezeptor-modulatoren
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US8247530B2 (en) * 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
US20090305960A1 (en) * 2008-06-09 2009-12-10 Palatin Technologies, Inc Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
JP5628796B2 (ja) 2008-06-09 2014-11-19 パラティン テクノロジーズ,インコーポレイテッドPalatin Technologies,Inc. 性的不能の治療用のメラノコルチンレセプタ特異的ペプチド
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
RU2404793C1 (ru) 2009-06-04 2010-11-27 Общество с ограниченной ответственностью Био Пептид Стимулятор половой, сексуальной и репродуктивной функции
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (de) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-gebrückte melanocortinrezeptorspezifische peptide
EP2504351A4 (de) 2009-11-23 2013-10-30 Palatin Technologies Inc Melanocortin-1-rezeptor-spezifische lineare peptide
WO2011063366A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
RU2507212C2 (ru) 2012-03-28 2014-02-20 Общество С Ограниченной Ответственностью "Айвикс" Способ получения рекомбинантного пептида и полученный пептид
RU2508117C1 (ru) * 2012-11-01 2014-02-27 Геннадий Алексеевич Бабкин Способ нормализации репродуктивной функции
EP2968469A4 (de) 2013-03-15 2016-08-31 Longevity Biotech Inc Peptide mit nichtnatürlichen aminosäuren und verfahren zur herstellung und verwendung davon
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
WO2015069130A1 (ru) * 2013-11-08 2015-05-14 Геннадий Алексеевич БАБКИН Способ нормализации репродуктивной функции

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649191A (en) * 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
DE3851002T2 (de) * 1987-05-22 1995-02-02 University Patents Inc Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
DE3913954C2 (de) * 1989-04-27 1991-08-29 Georg Dr. 7800 Freiburg De Stief
DE69429768T2 (de) * 1993-04-05 2002-09-19 Competitive Tech Inc Diagnose und behandlung von erektilen funktionsstörungen

Also Published As

Publication number Publication date
JP3204510B2 (ja) 2001-09-04
DE69429768D1 (de) 2002-03-14
JPH10509130A (ja) 1998-09-08
US5576290A (en) 1996-11-19
WO1994022460A1 (en) 1994-10-13
EP0696919A1 (de) 1996-02-21
EP0696919B1 (de) 2002-01-30
EP0696919A4 (de) 1998-03-11
US6051555A (en) 2000-04-18

Similar Documents

Publication Publication Date Title
DE69605676T2 (de) Herzüberwachungs-vorrichtung und anwendung
DE69008010T2 (de) Sauerstoffdelignifizierung und enzymatische Behandlung.
DE69510689D1 (de) Aufeinanderfolgende abgabe von tüchern und entsprechende abgabevorrichtung
DE69431355D1 (de) Chirurgisches ultraschallgerät und sein herstellungsverfahren
FI955133A0 (fi) Jäteveden käsittelyprosessi ja laite
DE69213079T2 (de) Fluidansaugvorrichtung und Fluidbehandlungsgerät
AT110955T (de) Haarbehandlungsmittel und verfahren.
DE69012124T2 (de) Verbesserungen bei der behandlung von zähnen.
BR9007938A (pt) Metodo e aparelho o tratamento de glaucoma
NO962784D0 (no) Behandling av arteriosklerose og xantom
DE29705934U1 (de) Diagnose- und Behandlungsvorrichtung für Zähne
DE69804793T2 (de) Klinisches und/oder chirurgisches trainingsgerät
DE719145T1 (de) Stickstoffoxyd abgebendes präparat und verfahren zur behandlung von analen erkrankungen
DE69403823T2 (de) Substituierte Phenylsulfonamine als selektive B3-Agonisten zur Behandlung von Diabetes und Fettleibigkeit
DE69524682D1 (de) Mittel zur Behandlung von Wunden
DE69431038D1 (de) System zur intravaskulären behandlung von arrhythmien
DE3855489D1 (de) Behandlung von Hautfalten
DE69405251D1 (de) Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika
FI963798A0 (fi) Menetelmä ja laite erektiohäirion diagnosoimiseksi
ATA87990A (de) Korrosionsbestaendige und verschleissfeste cobalt-basis-legierung
DE69327402D1 (de) Vorbeugung und behandlung der peripheren neuropathie
DE69328550T2 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
DE69505657T2 (de) Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren
DE69331762T2 (de) "heat shock"-proteine und behandlung von tumoren
DE69500699D1 (de) Einrichtung zur behandlung und zur konditionierung von motorkühlmittel